Get 40% Off
🔥 This hedge fund gained 26.16% in the last month. Get their top stocks with our free stock ideas tool.See stock ideas

HCW Biologics Stock Soars after Receiving FDA Clearance for Phase 1 Trial

Published 10/28/2021, 10:14 AM
Updated 10/28/2021, 10:16 AM
© Reuters.
HCWB
-

By Sam Boughedda

Investing.com — HCW Biologics Inc (NASDAQ:HCWB) has been given a boost after the Food and Drug Administration gave the company clearance to proceed with a Phase 1b Clinical Trial for its pancreatic cancer drug.

Called HCW9218, the drug  is the company's lead candidate, which is why HCW's share price has seen a significant reaction to the news, surging to a high of $7.05 following Wednesday's close at $2.92.

Hing C. Wong, Founder and CEO of HCW Biologics, said: "The FDA's clearance to proceed with our first-in-human trial for HCW9218 in pancreatic cancer is an important milestone for HCW Biologics and our efforts to advance the development of potentially groundbreaking immunotherapy candidates for cancer and other age-related diseases.

On Wednesday, the company announced Lisa Giles and Gary Winer as new members of its board. 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.